company background image
RAD logo

Radiopharm Theranostics ASX:RAD Stock Report

Last Price

AU$0.028

Market Cap

AU$60.8m

7D

-20.0%

1Y

-69.9%

Updated

18 Jan, 2025

Data

Company Financials +

Radiopharm Theranostics Limited

ASX:RAD Stock Report

Market Cap: AU$60.8m

RAD Stock Overview

Engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. More details

RAD fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Radiopharm Theranostics Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Radiopharm Theranostics
Historical stock prices
Current Share PriceAU$0.028
52 Week HighAU$0.09
52 Week LowAU$0.021
Beta0.85
1 Month Change33.33%
3 Month Change0%
1 Year Change-69.89%
3 Year Change-92.33%
5 Year Changen/a
Change since IPO-93.00%

Recent News & Updates

Recent updates

We're A Little Worried About Radiopharm Theranostics' (ASX:RAD) Cash Burn Rate

Jan 06
We're A Little Worried About Radiopharm Theranostics' (ASX:RAD) Cash Burn Rate

Here's Why Radiopharm Theranostics (ASX:RAD) Must Use Its Cash Wisely

Sep 02
Here's Why Radiopharm Theranostics (ASX:RAD) Must Use Its Cash Wisely

Shareholder Returns

RADAU BiotechsAU Market
7D-20.0%-2.7%0.1%
1Y-69.9%0.6%9.9%

Return vs Industry: RAD underperformed the Australian Biotechs industry which returned 0.6% over the past year.

Return vs Market: RAD underperformed the Australian Market which returned 9.9% over the past year.

Price Volatility

Is RAD's price volatile compared to industry and market?
RAD volatility
RAD Average Weekly Movement20.7%
Biotechs Industry Average Movement9.4%
Market Average Movement7.9%
10% most volatile stocks in AU Market16.5%
10% least volatile stocks in AU Market2.9%

Stable Share Price: RAD's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: RAD's weekly volatility has increased from 14% to 21% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2021n/aRiccardo Canevariwww.radiopharmtheranostics.com

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors.

Radiopharm Theranostics Limited Fundamentals Summary

How do Radiopharm Theranostics's earnings and revenue compare to its market cap?
RAD fundamental statistics
Market capAU$60.84m
Earnings (TTM)-AU$47.95m
Revenue (TTM)AU$1.96m

31.1x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RAD income statement (TTM)
RevenueAU$1.96m
Cost of RevenueAU$21.61m
Gross Profit-AU$19.65m
Other ExpensesAU$28.30m
Earnings-AU$47.95m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.022
Gross Margin-1,003.25%
Net Profit Margin-2,448.23%
Debt/Equity Ratio0%

How did RAD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/18 21:45
End of Day Share Price 2025/01/17 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Radiopharm Theranostics Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Justin WalshJonesTrading Institutional Services, LLC
null nullLodge Partners Pty Ltd.